Rheumatology 2000; 39: 28-33
© 2000 British Society for Rheumatology
Original Papers |
Economic burden of rheumatoid arthritis: a systematic review
School of Health Policy and Practice, Elizabeth Fry Building, University of East Anglia, Norwich NR4 7TJ, UK
Objective. To summarize the state of knowledge with regard to the economic impact of rheumatoid arthritis (RA) and to highlight any weaknesses in the work conducted to date, so as to inform future RA cost-of-illness studies.
Methods. Four computerized literature databases were searched to identify all the literature relevant to this review. Seven elements indicating a quality cost-of-illness study were established and used to appraise the literature identified critically. Where possible, costs reported by the different studies were converted to 1996 US dollars using the consumer price index for medical care.
Results. Total average medical costs were reported to range from US$5720 (UK£3575) to US$5822 (UK£3638). Medication constituted between 8 and 24% of total medical costs, physician visits between 8 and 21%, and in-patient stays between 17 and 88%. The average number of days absent from work due to a person's RA was reported to range from 2.7 to 30 days/year.
Conclusion. The economic impact of RA in terms of cost was reported to be substantial by all studies reviewed. However, methodological problems meant that discrepancies in the average (per person) annual cost of RA existed across studies.
KEY WORDS: Rheumatoid arthritis, Economics, Costs, Review
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Westhoff, F. Buttgereit, E. Gromnica-Ihle, and A. Zink Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis Rheumatology, July 1, 2008; 47(7): 980 - 984. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hawboldt and M. Bader Intramuscular Methotrexate-Induced Aseptic Meningitis Ann. Pharmacother., November 1, 2007; 41(11): 1906 - 1911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. E. Walsh, P. Minnock, C. Slattery, N. Kennedy, F. Pang, D. J. Veale, B. Bresnihan, and O. FitzGerald Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis Rheumatology, July 1, 2007; 46(7): 1148 - 1152. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. M. Verstappen, J. W. G. Jacobs, A. A. Kruize, J. C. Ehrlich, G. A. van Albada-Kuipers, H. Verkleij, E. Buskens, and J. W. J. Bijlsma Trends in economic consequences of rheumatoid arthritis over two subsequent years Rheumatology, June 1, 2007; 46(6): 968 - 974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuek, B. L Hazleman, and A. J K Ostor Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Postgrad. Med. J., April 1, 2007; 83(978): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Huscher, S Merkesdal, K Thiele, H Zeidler, M Schneider, A Zink, and for the German Collaborative Arthritis Centres Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany Ann Rheum Dis, September 1, 2006; 65(9): 1175 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kavanaugh Pharmacoeconomic considerations in the treatment of psoriatic arthritis Rheumatology, July 1, 2006; 45(7): 790 - 791. [Full Text] [PDF]
|
|
|
|
|
|
A Kavanaugh Health economics: implications for novel antirheumatic therapies Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv65 - iv69. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J L Hulsemann, T Mittendorf, S Merkesdal, S Zeh, S Handelmann, J- M von der Schulenburg, H Zeidler, and J Ruof Direct costs related to rheumatoid arthritis: the patient perspective Ann Rheum Dis, October 1, 2005; 64(10): 1456 - 1461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kobelt, P. Lindgren, Y. Lindroth, L. Jacobson, and K. Eberhardt Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis Rheumatology, September 1, 2005; 44(9): 1169 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Keat, N. Barkham, A. Bhalla, K. Gaffney, H. Marzo-Ortega, S. Paul, F. Rogers, M. Somerville, R. Sturrock, P. Wordsworth, et al. BSR guidelines for prescribing TNF-{alpha} blockers in adults with ankylosing spondylitis. Report of a working party of the British Society for Rheumatology Rheumatology, July 1, 2005; 44(7): 939 - 947. [Full Text] [PDF]
|
|
|
|
|
|
D. James, A. Young, E. Kulinskaya, E. Knight, W. Thompson, W. Ollier, and J. Dixey Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years Rheumatology, March 1, 2004; 43(3): 369 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brennan, N. Bansback, A. Reynolds, and P. Conway Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology, January 1, 2004; 43(1): 62 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Sieper, J Braun, M Rudwaleit, A Boonen, and A Zink Ankylosing spondylitis: an overview Ann Rheum Dis, November 1, 2002; 61(90003): iii8 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P D M de Buck, R J van Amstel, P C Buijs, J H W Maasen, F J H van Dijk, J M W Hazes, and T P M V. Vlieland Communication between Dutch rheumatologists and occupational physicians in the occupational rehabilitation of patients with rheumatic diseases Ann Rheum Dis, January 1, 2002; 61(1): 62 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Lambert Medical therapy for rheumatoid arthritis--value for money? Rheumatology, September 1, 2001; 40(9): 961 - 964. [Full Text] [PDF]
|
|